SCI Pharmtech, Inc.
TWSE:4119.TW
90 (TWD) • At close November 1, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) TWD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 1,204.159 | 899.738 | 864.217 | 2,689.222 | 2,355.747 | 1,939.913 | 1,301.05 | 1,903.1 | 1,810.501 | 1,491.862 | 1,292.734 | 1,262.572 | 1,037.853 | 994.676 | 905.738 |
| Cost of Revenue
| 853.836 | 608.559 | 656.128 | 1,414.894 | 1,419.977 | 1,190.97 | 905.368 | 1,112.574 | 1,155.449 | 1,012.509 | 895.753 | 864.684 | 730.664 | 665.718 | 574.368 |
| Gross Profit
| 350.323 | 291.179 | 208.089 | 1,274.328 | 935.77 | 748.943 | 395.682 | 790.526 | 655.052 | 479.353 | 396.981 | 397.888 | 307.189 | 328.958 | 331.37 |
| Gross Profit Ratio
| 0.291 | 0.324 | 0.241 | 0.474 | 0.397 | 0.386 | 0.304 | 0.415 | 0.362 | 0.321 | 0.307 | 0.315 | 0.296 | 0.331 | 0.366 |
| Reseach & Development Expenses
| 49.094 | 39.649 | 30.347 | 43.365 | 38.917 | 36.851 | 33.089 | 35.644 | 35.391 | 36.119 | 32.088 | 32.118 | 37.985 | 34.66 | 31.368 |
| General & Administrative Expenses
| 79.193 | 82.156 | 54.976 | 68.637 | 91.446 | 77.988 | 41.884 | 71.845 | 64.182 | 77.338 | 100.464 | 64.891 | 50.496 | 54.294 | 57.233 |
| Selling & Marketing Expenses
| 61.736 | 50.404 | 49.108 | 111.927 | 108.286 | 117.359 | 86.169 | 166.58 | 115.792 | 70.53 | 58.57 | 49.03 | 32.638 | 27.318 | 28.087 |
| SG&A
| 140.929 | 132.56 | 104.084 | 180.564 | 199.732 | 195.347 | 128.053 | 238.425 | 179.974 | 147.868 | 159.034 | 113.921 | 83.134 | 81.612 | 85.32 |
| Other Expenses
| 217.939 | 263.85 | 8.158 | -554.156 | 13.425 | 8.73 | 9.688 | -8.742 | 21.259 | 54.112 | 2.922 | 3.01 | 6.539 | 2.096 | -0.657 |
| Operating Expenses
| 190.023 | 172.209 | 134.431 | 223.929 | 238.649 | 232.198 | 161.142 | 274.069 | 215.365 | 183.987 | 191.122 | 146.039 | 121.119 | 116.272 | 116.688 |
| Operating Income
| 372.936 | 404.299 | 63.305 | 469.712 | 705.2 | 516.745 | 234.54 | 516.457 | 439.687 | 295.366 | 205.859 | 251.849 | 186.07 | 212.686 | 214.682 |
| Operating Income Ratio
| 0.31 | 0.449 | 0.073 | 0.175 | 0.299 | 0.266 | 0.18 | 0.271 | 0.243 | 0.198 | 0.159 | 0.199 | 0.179 | 0.214 | 0.237 |
| Total Other Income Expenses Net
| -8.746 | -16.479 | 2.201 | -14.497 | 5.96 | 28.042 | 0.234 | -10.758 | 11.803 | 39.728 | -12.079 | -13.695 | -79.706 | -11.009 | -0.523 |
| Income Before Tax
| 364.19 | 387.82 | 65.506 | 455.215 | 711.16 | 544.787 | 234.774 | 505.699 | 451.49 | 335.094 | 193.78 | 238.154 | 106.364 | 201.677 | 214.159 |
| Income Before Tax Ratio
| 0.302 | 0.431 | 0.076 | 0.169 | 0.302 | 0.281 | 0.18 | 0.266 | 0.249 | 0.225 | 0.15 | 0.189 | 0.102 | 0.203 | 0.236 |
| Income Tax Expense
| 69.469 | 79.04 | 9.81 | 95.091 | 140.059 | 97.55 | 43.798 | 88.744 | 77.588 | 70.255 | 33.842 | 43.705 | 16.348 | 30.433 | 47.847 |
| Net Income
| 294.721 | 308.78 | 55.696 | 360.124 | 571.101 | 447.237 | 190.976 | 416.955 | 373.902 | 264.839 | 159.938 | 194.449 | 90.016 | 171.244 | 166.312 |
| Net Income Ratio
| 0.245 | 0.343 | 0.064 | 0.134 | 0.242 | 0.231 | 0.147 | 0.219 | 0.207 | 0.178 | 0.124 | 0.154 | 0.087 | 0.172 | 0.184 |
| EPS
| 2.7 | 2.83 | 0.51 | 3.3 | 5.24 | 4.17 | 1.79 | 3.96 | 3.83 | 2.84 | 1.72 | 2.58 | 1.16 | 2.23 | 2.2 |
| EPS Diluted
| 2.69 | 2.82 | 0.51 | 3.28 | 5.19 | 4.17 | 1.77 | 3.87 | 3.54 | 2.54 | 1.53 | 2.55 | 1.15 | 2.19 | 2.15 |
| EBITDA
| 518.23 | 494.911 | 127.013 | 603.015 | 841.931 | 676.769 | 358.718 | 640.039 | 591.105 | 478.191 | 319.597 | 350.418 | 305.512 | 307.161 | 306.4 |
| EBITDA Ratio
| 0.43 | 0.55 | 0.147 | 0.224 | 0.357 | 0.349 | 0.276 | 0.336 | 0.326 | 0.321 | 0.247 | 0.278 | 0.294 | 0.309 | 0.338 |